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Combination of Loop Diuretics With
Thiazide-Type Diuretics in Heart Failure
Jacob C. Jentzer, MD,* Tracy A. DeWald, RD, PHARMD, BCPS,*† Adrian F. Hernandez, MD*‡§
Durham, North Carolina
Volume overload is an important clinical target in heart failure management, typically addressed using loop di-
uretics. An important and challenging subset of heart failure patients exhibit fluid overload despite significant
doses of loop diuretics. One approach to overcome loop diuretic resistance is the addition of a thiazide-type di-
uretic to produce diuretic synergy via “sequential nephron blockade,” first described more than 40 years ago.
Although potentially able to induce diuresis in patients otherwise resistant to high doses of loop diuretics, this
strategy has not been subjected to large-scale clinical trials to establish safety and clinical efficacy. We summa-
rize the existing literature evaluating the combination of loop and thiazide diuretics in patients with heart failure
in order to describe the possible benefits and hazards associated with this therapy. Combination diuretic therapy
using any of several thiazide-type diuretics can more than double daily urine sodium excretion to induce weight
loss and edema resolution, at the risk of inducing severe hypokalemia in addition to hyponatremia, hypotension,
and worsening renal function. We provide considerations about prudent use of this therapy and review potential
misconceptions about this long-used diuretic approach. Finally, we seek to highlight the need for pragmatic clini-
cal trials for this commonly used therapy. (J Am Coll Cardiol 2010;56:1527–34) © 2010 by the American Col-
lege of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.06.034u
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seart failure is the leading hospital discharge diagnosis
mong elderly Americans, accounting for more than
million hospital admissions each year in the U.S. (1).
rognosis after heart failure hospitalization is poor, with
0% of patients rehospitalized within 6 months and 25% to
5% mortality at 1 year (2). Despite several clinical trials, no
ingle pharmacologic therapy has been clearly shown to
educe mortality or rehospitalization rates in acute heart
ailure (3). Congestion in acute heart failure syndromes
ppears to be more complicated than fluid accumulation
lone (4,5). The vast majority of patients admitted for
ecompensated heart failure are treated primarily with
ntravenous loop diuretics (LD), and until the recently
ompleted DOSE (Diuretic Optimization Strategies Eval-
ation) trial, there were limited prospective trial data eval-
rom the *Department of Medicine, Duke University School of Medicine, Durham,
orth Carolina; †Division of Clinical Pharmacology, Department of Medicine, Duke
niversity School of Medicine, Durham, North Carolina; ‡Division of Cardiology,
epartment of Medicine, Duke University School of Medicine, Durham, North
arolina; and the §Duke Clinical Research Institute, Duke University Medical
enter, Durham, North Carolina. This project was supported by grant number
18HS016964 from the Agency for Healthcare Research and Quality (AHRQ). The
ontent is solely the responsibility of the authors and does not necessarily represent the
fficial views of the AHRQ. Dr. Hernandez was supported by American Heart
ssociation Pharmaceutical Roundtable grant 0675060N. Dr. Hernandez reported
eceiving research support from Johnson & Johnson, Merck & Co., and Proventys and
onoraria from AstraZeneca, Amgen, Corthea, and Medtronic. All other authors
eport that they have no relationships to disclose.f
Manuscript received February 17, 2010; revised manuscript received April 30,
010, accepted June 1, 2010.ating the efficacy or safety of diuretics (6). Before the
OSE trial, many thought patients with acute heart failure
eceiving high doses of LD were at increased risk of serious
dverse events (7) and renal failure (8). Patients with heart
ailure who are resistant to LD have poor outcomes, which
ay be a function of their more severe underlying disease
rocess (9).
vercoming Diuretic Resistance
n Edematous States
luid overload refractory to conventional treatment with
D can complicate acute or chronic heart failure man-
gement. Diuretic resistance in heart failure results from
n interaction between the pathophysiology of sodium
etention in heart failure and the renal response to
iuretic therapy (Fig. 1) (10). By eliciting significant
ounter-regulatory responses during acute and chronic
se, several effects such as the “braking phenomenon,”
ost-diuretic effect, rebound sodium retention, and renal
daptation lead to diuretic resistance. The braking phe-
omenon describes an acute reduction in diuretic efficacy
ith repeated LD dosing, while the post-diuretic effect
efers to increased sodium retention after the LD has
orn off. Rebound sodium retention occurs when chronic
D use leads to increased distal nephron sodium reab-
orption. Renal adaptation occurs with prolonged expo-
ure to LD and is described as hypertrophy and hyper-
unction of distal tubule cells causing increased local sodium
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which markedly limits the re-
sponse to LD (11,12). Distal tu-
bule hypertrophy also appears to
be an important contributor to
rebound sodium retention and
reduced response to chronic LD
therapy over time (13). The ac-
tivities of different diuretics
hould be considered to overcome the potential problems
ith diuretic resistance (Fig. 1).
Consideration of pharmacokinetic parameters of LD
herapies may help to optimize strategies for overcoming
iuretic resistance. Increasing LD doses is often considered
nitially to increase plasma drug concentrations and hope-
ully enhance LD effectiveness. Additional consideration
ay be given to drug half-life. For example, significant
Abbreviations
and Acronyms
CDT  combination diuretic
therapy
LD  loop diuretic(s)
TD  thiazide-type
diuretic(s)
Figure 1 Diuretic Resistance and the Nephron
Sites of diuretic action and sodium retention with suggested strategies to overcom
filtration rate (GFR). Percentage of filtered sodium reabsorbed in each nephron seg
filtered sodium and proximal reabsorption is increased in sodium-retaining states
post-diuretic effect. Loop of Henle is the site of action of loop diuretics (LD) and a
occur here due to up-regulation of the Na/K/Cl cotransporter after exposure to LD
cotransporter (inhibited by thiazide-type diuretics [TD]) but size and function may in
tion. Distal nephron collecting duct is the site of regulated sodium and water reab
(ENaC) and aquaporins, respectively. Multiple mechanisms of diuretic resistance m
Figure illustration by Craig Skaggs based on the author’s description and an exam
N Engl J Med 2009;36:2153–64. ACEI  angiotensin-converting enzyme inhibitor;ifferences in the half-life of intravenous torsemide and
urosemide in patients with heart failure have been docu-
ented (14). To overcome diuretic resistance, a more
requent administration schedule might be preferred for
ntravenous furosemide with a mean half-life of 1.5 h
ompared with intravenous torsemide with a mean half-life
f 6.3 h. Ideally, critical evaluations of the effectiveness of a
rug regimen occur at steady state when the rate of drug
dministration is equal to the rate of drug elimination. In
ost clinical situations, steady state can be assumed after 4
alf-lives. Similarly, in most clinical situations, it can be
ssumed that all drug has been eliminated after 4 half-lives
ave passed without further drug administration. If the
osing interval for intravenous LD therapies extends be-
ond 4 half-lives, it is expected that there will be periods of
ime when no drug is available for pharmacologic activity
nd suboptimal effect may be observed. Thus, optimization
etic resistance. Sodium delivery into tubular fluid is determined by glomerular
is denoted in parentheses. Proximal convoluted tubule reabsorbs the majority of
the control of neurohormones (alpha-1 adrenergic, angiotensin-II), producing the
most of the sodium that escapes the proximal tubule; braking effect appears to
l convoluted tubule reabsorbs a lesser amount of filtered sodium via NaCl
e dramatically after chronic LD exposure, accounting for rebound sodium reten-
n under control of aldosterone and vasopressin via epithelial sodium channels
cur in a single patient, requiring a systematic approach to diuretic therapy.
phron from Ernst ME, Moser M. Use of diuretics in patients with hypertension.
angiotensin-receptor blocker.e diur
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vercome apparent diuretic resistance.
After optimization of LD, other causes of diuretic resis-
ance should be considered, particularly braking and post-
iuretic effects. Physiologically, sequential nephron block-
de by addition of a second diuretic class to ineffective
ptimized LD therapy can address other forms of diuretic
esistance. By blocking distal tubule sodium reabsorption,
hiazide-type diuretics (TD) can antagonize the renal ad-
ptation to chronic LD therapy and potentially improve
iuretic resistance due to rebound sodium retention (12,15).
everal of the other mechanisms of action of different
iuretic classes are summarized in Table 1 (16).
ombination Diuretic Therapy
o Overcome Resistance to LD
he earliest studies examining the addition of TD to LD in
atients with resistant edema due to heart failure or other
dematous states date back more than 40 years to the early
ays of diuretic therapy (17). Despite more than 50 pub-
ished reports, the experience is limited to 300 heart failure
atients (Table 2) (17–45), raising many questions about
his potent diuretic combination. The aggregate body of
iterature is limited by the small size of studies, study design
ith lack of control groups, heterogeneous patient popula-
ions, wide variation in diuretic regimens, and focus on
hysiologic rather than clinical outcomes. In fact, most
tudies have evaluated weight loss or clearance of persistent
dema as the end point. The main findings date back to a
eries of randomized, cross-over laboratory studies per-
ormed in the early 1970s that showed that TD increased
rine sodium excretion and urine volume compared with
ncreasing the LD dose (21,25).
Among the largest randomized clinical trials was a
0-patient study comparing 2 different TD added to exist-
ng LD therapy (41). In a 2  2 factorial design, in patients
ith New York Heart Association functional class III/IV
eart failure symptoms despite intravenous furosemide 80
g twice daily were randomized to the addition of ben-
echanism of Action of Diuretic ClassesTable 1 Mechanism of Action of Diuretic Classes
Drug Class Examples
Carbonic anhydrase inhibitors Acetazolamide Inhibition of proximal c
Loop diuretics Furosemide
Bumetanide
Torsemide
Inhibition of Na/K/2Cl
Thiazide-type diuretics Hydrochlorothiazide
Metolazone
Inhibition of Na/Cl cotr
Potassium-sparing diuretics Amiloride
Triamterene
Inhibition of aldosteron
Aldosterone antagonists Spironolactone
Eplerenone
Inhibition of aldosteron
Vasopressin antagonists Conivaptan*
Tolvaptan
Inhibition of V2 recepto
Conivaptan has nonselective V1A/V2 antagonism.roflumethiazide 10 mg daily versus metolazone 10 mg eaily as well as limited duration (3 days) versus indefinite
uration (physician’s discretion) of combination diuretic
herapy (CDT). Both drugs significantly augmented diure-
is and produced a similar (5 kg) mean weight loss over 5
o 6 days; diuresis continued for the same amount of time
egardless of CDT treatment duration. Clinical response
ccurred in 92.5%, with symptomatic improvement allow-
ng hospital discharge in 90% of patients. Metolazone had
reater adverse effects on potassium levels and renal function
han bendroflumethiazide, but no clinical adverse effects
ere reported; nearly two-thirds of patients developed
ignificant hypokalemia (serum potassium 3.5 mEq/l).
Other observational studies have shown the addition of
oderate-dose TD often induced diuresis in patients resis-
ant to very large doses of LD, with or without potassium-
paring diuretics (43). Outpatients previously dependent on
ntermittent intravenous LD could be maintained on oral
iuretics after addition of metolazone (35). The majority of
npatients with acute heart failure refractory to maximal
herapy, including intravenous LD, responded to the addi-
ion of low-dose metolazone within 48 to 72 h, allowing
ospital discharge; metolazone nonresponders had a partic-
larly poor prognosis (37). In a small study, the addition of
hlorothiazide to LD during an episode of decompensated
eart failure allowed clinical stabilization and remained
ffective for prevention of edema reaccumulation after hos-
ital discharge for 2 years in some patients (42).
D in Combination Therapy: Common
isconceptions and Evidence of a Class Effect
lthough there are some commonly held beliefs about TD
n CDT, the literature varies regarding many of these
oncepts. Metolazone is touted as being superior to other
D for CDT, possibly due to inhibition of proximal tubule
unction (46). Direct comparison of metolazone with ben-
roflumethiazide in a randomized, double-blind trial found
o superiority of metolazone (41); comparison of quinetha-
one (metolazone’s parent compound) with bendroflume-
hiazide revealed similar effects of both drugs (21). How-
Mechanism of Action
ted tubule sodium bicarbonate reabsorption
sporter in thick ascending loop of Henle
rter in distal convoluted tubule
onsive epithelial Na channel (ENaC) in distal nephron  collecting tubule
ptors in distal nephron  collecting tubule, reducing Na channel and Na/K ATPase
istal nephron  collecting tubule, reducing aquaporin (water) channel densityonvolu
cotran
anspo
e-resp
e rece
rs in dver, a response to metolazone plus furosemide was
Summary of Reviewed Studies in Heart Failure PatientsTable 2 Summary of Reviewed Studies in Heart Failure Patients
First Author (Ref. #), Year Patients Design TD Dose LD Dose Benefits Adverse Events
Robson et al. (18), 1964 1 CHF Observational HCTZ 100 mg IV FSM 50–100 mg IV 
1–5 mg/min
None Not reported
Dettli and Spring (17), 1966 18 mixed
edematous
Observational HCTZ 200 mg FSM 30–240 mg/day Improved diuresis, similar to 4 higher
FSM dose
Hypochloremic alkalosis  hypokalemia
Olesen et al. (19), 1970 24 CHF Randomized
active-control
QEZ 50–100 mg/day FSM 40–80 mg/day Superior diuresis to doubled FSM dose in
mild CHF only
Hypokalemia (0.5 mEq/l) bigeminy
Olesen et al. (20), 1971a 12 CHF Randomized
active-control
QEZ 50 mg/day FSM 40 mg/day Doubled UNa, mean weight loss 0.5 kg/day Not reported
Olesen et al. (21), 1971b 24 CHF Randomized
active-control
QEZ 50 mg/day
BDFZ 5 mg/day
FSM 80 mg BID Doubled UNa, weight loss 0.7–0.8 kg/day Hypokalemia (0.3 mEq/l)
Beck and Asscher (22), 1971 1 CHF Observational MTZ 5 mg/day FSM 80 mg/day Clearance of edema Hypokalemia
Gunstone et al. (23), 1971 13 CHF Observational MTZ 2.5–10 mg/day FSM 120–400 mg/day 2 kg weight loss over 4 days in 2/3 overall Azotemia in most patients, hypokalemia
Asscher (24), 1974 4 CHF Observational MTZ 5 mg/day FSM 500 mg/day Mean weight loss 8.1 kg Hypokalemia
Sigurd et al. (25), 1975 18 CHF Randomized
active-control
BDFZ 5 mg/day BMT 2 mg BID Doubled UNa, mean weight loss 0.8 kg/day Hypokalemia (0.45 mEq/l)
Epstein et al. (26), 1977 1 CHF Observational MTZ 5 mg/day FSM 160 mg PO BID Increased UNa even with severely reduced GFR Hypokalemia
Ram and Reichgott (27), 1977 5 CHF  CKD Observational MTZ 5 mg/day FSM 160–320 mg/day Mean weight loss 4.4 kg Hypokalemia (0.3 mEq/l), creatinine1 28%
Sigurd and Olesen (28), 1978 18 CHF Randomized
active-control
BDFZ 5 mg/day BMT 2 mg BID Tripled UNa, similar effect to aminophylline
200 mg BID
None
Furrer et al. (29), 1980 11 ADHF Observational MTZ 2.5 mg/day FSM 40–370 mg/day Mean 6.7 kg weight loss Excessive/uncontrolled diuresis
Ghose and Gupta (30), 1981 3 CHF Observational MTZ 2.5–5 mg/day Various 0.3–0.6 kg/day weight loss Not reported
Allen et al. (31), 1981 4 CHF Observational MTZ 5 mg/day FSM 1–2 g/day 8–13L diuresis over 4–5 days Hypokalemia
Bamford (32), 1981 1 CHF Observational MTZ 5 mg QOD FSM 500 mg/day 13 kg weight loss Not reported
Grosskopf et al. (33), 1986 10 ADHF Randomized
active-control
MTZ 5 mg/day FSM 120 mg/day IV Improved diuresis, weight loss 2.2 kg
over 3 days
Hypokalemia (0.4 mEq/l)
Gage et al. (34), 1986 14 CHF Observational MTZ 2.5 mg QOD up to
15 mg/week
FSM 160 mg/day Mean 4.4 kg weight loss  edema clearance Hypokalemia (0.6 mEq/l), BUN1 33%
Aravot et al. (35), 1989 12 CHF Observational MTZ 2.5–5 mg
2/week
FSM 160 mg/day Eliminated need for IV diuresis Not reported
Friendland and Ledingham (36), 1989 1 ADHF Observational MTZ 5–10 mg/day FSM 240 mg/day IV 16 kg weight loss Not reported
Kiyingi et al. (37), 1990 10 CHF Observational BDFZ 10 mg/day FSM 200–400 mg/day IV Mean weight loss 7.7 kg Hypokalemia (2.9 mEq/l) in 20%
Channer et al. (38), 1990 17 ADHF Observational MTZ 1.25–10 mg/day FSM 250–500 mg/day PO Responders (71%) had mean 8.3 kg
weight loss  d/c home
Hypokalemia, creatinine1 25%
Kröger et al. (39), 1991 10 ADHF Observational MTZ 2.5–5 mg/day FSM 80–500 mg/day Mean 8.9 kg weight loss Hyponatremia, hypokalemia
Dormans and Gerlag (40), 1993 8 CHF Observational HCTZ 25–100 mg/day FSM 500– 4000 mg/day Doubled UNa, mean 1.3 kg/day weight loss Creatinine1 50%, ClCr2 33%, hypokalemia
Channer et al. (41), 1994 40 ADHF Randomized
active-control
MTZ 10 mg/day
BDFZ 10 mg/day
FSM 80 mg IV BID 5–5.6 kg mean weight loss, hospital d/c
in 90%
Hypokalemia (3.5 mEq/l) in 65%
Mouallem et al. (42), 1995 32 ADHF Observational CTZ 500 mg/day FSM 160–320 mg/day Mean 4.8 kg weight loss, clearance of edema Hypokalemia (0.4 mEq/l)
Dormans and Gerlag (43), 1996 20 ADHF Observational HCTZ 25–100 mg/day FSM 250–4000 mg/day Doubled UNa, mean weight loss 6.7 kg,
d/c home in 70%
Hypokalemia (0.8 mEq/l),
persistent dehydration
Vanky et al. (44), 1997 20 post-CABG Observational HCTZ 50 mg/day 
amiloride 5 mg/day
FSM 80 mg/day Mean 2.3 kg weight loss after one dose None
Rosenberg et al. (45), 2005 21 CHF Observational MTZ 2.5–5 mg/day FSM mean 260 mg/day Mean 2 kg weight loss  10/8 mm Hg
BP reduction
BUN1 58%, hypokalemia (0.8 mEq/l),
creatinine1 27%
Some studies included patients with diagnosis other than heart failure.
ADHF  acute decompensated heart failure (inpatients); BDFZ  bendroflumethiazide; BID  twice daily; BMT  bumetanide; BP  blood pressure; BUN  blood urea nitrogen; CABG  coronary artery bypass grafting; CHF  chronic heart failure (outpatients); CKD; 
chronic kidney disease; ClCr  creatinine clearance; CTZ  chlorothiazide; d/c  discharge; FSM  furosemide; GFR  glomerular filtration rate; HCTZ  hydrochlorothiazide; IV  intravenous; MTZ  metolazone; PO  oral; QEZ  quinethazone; QOD  every other day;
UNa  urine sodium.
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November 2, 2010:1527–34 Combination Diuretic Therapy in Heart Failureocumented in a single patient resistant to chlorothiazide
lus furosemide (24). Numerous TD have been evaluated in
ombination with various LD with similar results overall,
nd no clear evidence that any single TD is superior,
uggesting a class effect. The most commonly used TD were
etolazone, bendroflumethiazide, quinethazone, and hy-
rochlorothiazide. In addition to metolazone (45), LD
ugmentation was demonstrated using chlorothiazide
13,42), hydrochlorothiazide (43,47), quinethazone (20,21),
ndapamide (48), bendroflumethiazide (21,25), and butizide
49). Metolazone has been suggested to be superior to other
D in patients with advanced kidney disease (24,50), but
ther TD augment the response to LD, even in patients
ith advanced renal failure (26,47,49,51). Finally, the as-
ertion that a TD should be given at least 30 min before the
D was not studied in any article we reviewed (52). Most
tudies reporting benefits of CDT administered the 2 drugs
t the same time. Metolazone has slow and variable absorp-
ion in edematous patients, such that the peak effect occurs
nly after several hours (15,45). The benefit of TD (with
heir long duration of action) added to LD appears to be
rimarily in maintaining diuresis after the shorter-acting
D has worn off (49,53).
nticipated Benefits of CDT
iven the baseline differences between the patient popula-
ions and the variations in diuretic regimens evaluated, it is
ifficult to quantify the effects of adding a TD to LD
herapy. Across studies, mean daily weight loss was variable,
ith 1 kg per day more typical but as much as 3 to 5 kg over
he first 24 h reported (24). Total weight reductions of 5 to
kg over several days in edematous patients were usual, but
eight loss 10 kg was described by several reports
37,42,43) and weight loss 20 kg was rarely reported (24).
he response rate to CDT varied based on the patient
opulation, ranging from 70% to 75% in more severely ill
atients (37,43,45) to 90% in many studies. In 1 obser-
ational study, lower baseline serum potassium identified
atients less likely to respond to the addition of metolazone
o existing LD therapy (45).
Potential benefits of CDT include fluid removal with
esolution of volume overload and congestion, even in
atients with impaired renal function refractory to LD
lone. Improved diuresis and relief of fluid overload could
acilitate earlier hospital discharge and/or prevent rehospi-
alization to reduce the total number of hospital days,
lthough it has been difficult to correlate weight loss during
eart failure hospitalization with subsequent outcomes (54).
DT has been associated with improved quality of life in
ome patients with heart failure (41,45). Heart failure
herapies should ideally improve mortality, but CDT may
ot provide such a benefit, considering the powerful neu-
ohormonal activation produced beyond the effect of a LD
lone (13) and lack of proven mortality benefit with LD (6).etolazone use has been associated with poor outcomes in ehronic heart failure, but may be a marker of increased
isease severity (9). The anticipated benefits of CDT at a
ow cost make this a potentially attractive therapeutic
ption; increased urine sodium concentration with CDT
vercomes 1 of the limitations of LD monotherapy for
uid removal. CDT has not been directly compared with
ltrafiltration for fluid removal in heart failure, and
ltrafiltration remains an important modality for refrac-
ory fluid overload (55).
dverse Effects of CDT
linically important adverse effects with CDT are common,
equiring careful monitoring of serum electrolytes and renal
unction (56). Hypokalemia is particularly frequent and
eductions in serum potassium from 0.4 to 0.8 mEq/l are
ommon despite aggressive potassium supplementation.
otassium-sparing diuretics such as spironolactone can
educe but do not entirely prevent potassium loss (21,25).
rine potassium loss and resultant hypokalemia tend to
orrelate with total urine sodium excretion and sodium
oncentration in the final urine. TD produce greater urine
otassium loss per unit of urine sodium excretion than LD,
nd CDT is particularly prone to massive urine potassium
xcretion, especially with higher baseline LD doses (47). In
elect hospitalized patients prone to hypokalemia, twice-
aily monitoring of potassium levels may be needed, with
ggressive supplementation of potassium deficits. Hypoka-
emia is often associated with hypochloremic (chloride-
esponsive) metabolic alkalosis because urine chloride losses
ypically exceed urine sodium losses; hypomagnesemia often
ccurs and can worsen hypokalemia. Hypokalemia, with or
ithout hypomagnesemia, may increase the risk of cardiac
rrhythmias, particularly in patients taking digoxin or anti-
rrhythmic agents. Diuretic-induced electrolyte distur-
ances may contribute to arrhythmic death in heart failure
atients (57). Hyponatremia can occur because the increase
n urine sodium excretion is greater than the increase in
rine water excretion with more hypertonic urine after
DT than after LD alone. Hyponatremia appears less
ommon than hypokalemia and was rarely symptomatic but
an be a marker of adverse heart failure outcomes (58).
assive diuresis with several liters of urinary fluid loss per
ay has been reported (24), potentially leading to progres-
ive volume depletion requiring fluid resuscitation (40).
ypotension can occur, with a mean reduction of 10/8 mm
g in blood pressure recorded in 1 study (45).
enal Function and CDT
hanges in serum creatinine and creatinine clearance with
DT may be highly variable. Early short-term controlled
tudies did not reveal a significant acute reduction in
reatinine clearance when a TD was added to existing LD
herapy (21,25); later controlled studies support this con-
lusion (33,49). Several studies reported severe, albeit gen-
rally reversible, azotemia developing in patients treated
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Combination Diuretic Therapy in Heart Failure November 2, 2010:1527–34ith CDT, particularly in the setting of more advanced
aseline renal dysfunction with higher baseline serum cre-
tinine (59). The rise in blood urea nitrogen was usually
reater than the rise in serum creatinine (26,34,41,45) and
ypically stabilized after 3 to 5 days (51). Increases in serum
reatinine on the order of 20% to 30% were frequently
eported. TD alone initially produce a reversible reduction
n glomerular filtration rate during peak natriuresis (47),
hich may be attenuated by the addition of LD (53).
hronic TD use is 1 predictor of worsening renal function
n chronic heart failure patients (60), and the potential for
orsening renal function is an important concern with
DT, given the adverse prognosis associated with worsen-
ng renal function in patients with heart failure (61). A
ecrease in serum creatinine can be seen after diuresis with
DT, depending on the hemodynamic state of the patient
nd the pathophysiology of their underlying renal dysfunc-
ion, potentially by relief of renal venous congestion (62).
n initial rise in serum creatinine may be followed by a
ustained fall as diuresis occurs (41). Impaired renal function
ith diuretic therapy can result from direct alterations in
lomerular hemodynamics due to neurohormonal and in-
rarenal feedback mechanisms or from overt volume deple-
ion (63). When excessive diuresis occurs, withdrawal of
oth diuretics is necessary due to the prolonged half-life of
D, which prolongs further in the presence of significant
enal insufficiency (46).
se of CDT in Clinical Practice
eading professional society guidelines all recommend use
f combined LD and TD therapy as 1 of several approaches
o fluid overload refractory to LD monotherapy, with a
evel of Evidence: C (expert opinion only) (2,50,64). A
otal of 5 sources were cited in support of this recommen-
ation (12,15,26,41,56), none of which included a placebo-
ontrolled trial; 1 was a randomized trial without placebo
ontrol (41).
Use of CDT requires weighing the known risks and
otential benefits, summarized in Table 3. Based on the
vailable literature, general recommendations can be made
egarding prudent use of CDT in heart failure patients,
otential Benefits and Adverse Effects of CDTTable 3 Potential Benefits and Adverse Effects of CDT
Potential Benefits Potential Adverse Effects
Overcoming diuretic resistance Hypokalemia
Relief of fluid overload  edema Worsening renal function/azotemia
Weight loss Hyponatremia
Low drug cost Hypochloremic metabolic alkalosis
Symptomatic improvement Hypotension
Decrease in systemic congestion Hypovolemia/dehydration
Diuresis in chronic renal failure Worsening hepatic encephalopathy
Improved ventricular function Cardiac arrhythmias/ectopy
Hospital discharge Hypomagnesemia
Prevention of readmission HyperuricemiaDT  combination diuretic therapy.
rimilar to previously published recommendations about use
f metolazone (46). Suggested considerations regarding
DT are summarized in Table 4. CDT is only appropriate
or patients with gross fluid overload refractory to optimized
oses of intravenous LD, especially in patients with chronic
ecompensated systolic heart failure and impaired renal
unction. Adequate doses of LD can be defined as 160 to
20 mg/day intravenous furosemide in divided doses or by
ontinuous infusion; this was the usual dose range used in
tudies of CDT. Carefully selected patients with advanced,
efractory, or end-stage (stage D) systolic heart failure may
e candidates for outpatient CDT as a means to prevent
ecurrent hospitalization for fluid overload, although this
pproach is not well-studied and requires close follow-up
2,34,37,50,64). CDT should not be used in patients with
eripheral edema due to local effects such as venous stasis
ather than total-body fluid overload due to a sodium-
etaining state. CDT is not an established or recommended
pproach to hypertension control in the absence of gross
uid overload (59). CDT is only expected to be effective in
atients with diuretic resistance due to distal tubule hyper-
rophy from chronic LD exposure, and other causes of
iuretic resistance should be carefully excluded.
Initiation of CDT should be done with careful observa-
ion and frequent monitoring of renal function and electro-
ytes. An equivalent dose of any TD should be effective
Table 5); longer-acting agents (e.g., metolazone) may be
ore useful for 2 to 3 times weekly dosing. A starting dose
mportant Considerations Regarding CDTTable 4 Important Considerations Regarding CDT
● Addition of thiazide-type diuretics can induce diuresis in patients refractory to
massive loop diuretic doses
● Combination of loop  thiazide-type diuretics can be effective in patients with
advanced chronic kidney disease
● Synergistic effects of thiazide-type diuretics on diuresis appear to be a class
effect seen with all drugs studied
● Potentially dangerous hypokalemia can develop with CDT, warranting close
laboratory monitoring
● Reversible increases in serum creatinine may be seen but are not the rule;
reductions in creatinine can occur as well
● Safety and effects on morbidity and mortality with CDT are unknown
DT  combination diuretic therapy.
osing and Duration of Action of TDTable 5 Dosing and Duration of Action of TD
Thiazide-Type
Diuretic
Equipotent
Dose, mg
Maximum Daily
Dose, mg Duration of Action
Bendroflumethiazide* 2.5 20 12–24 h (up to 48 h)†
Chlorothiazide 250 1,000 6–12 h (up to 24 h)†
Chlorthalidone 12.5 100 24–72 h†
Hydrochlorothiazide 25 200 6–12 h (up to 24 h)†
Indapamide 2.5 5 36 h
Methylclothiazide 2.5 20 24 h
Metolazone 2.5 20 12–24 h (up to 48 h)†
Quinethazone* 25 200 12–24 h†
Not currently available in the U.S. †Duration of action can prolong substantially in the presence of
enal insufficiency or chronic dosing. Adapted, with permission, from Hunt et al. (2).
TD  thiazide-type diuretics.
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November 2, 2010:1527–34 Combination Diuretic Therapy in Heart Failurequivalent to metolazone 2.5 mg daily is suggested; 2 to 3
imes weekly dosing is preferred for outpatient use rather
han daily dosing (64). TD dosing recommendations for
DT from the American College of Cardiology/American
eart Association guidelines include oral metolazone 2.5 to
0 mg once daily (or 2.5 to 5 mg once or twice daily), oral
ydrochlorothiazide 25 to 100 mg once or twice daily, or
ntravenous chlorothiazide 500 to 1,000 mg once or twice
aily (2). For inpatients, the initial dose can be repeated or
oubled each day in order to achieve desired diuresis,
ecognizing that TD tend to accumulate with repeated
osing in patients with impaired renal function, potentially
eading to accelerating diuresis. A more aggressive regimen
tarting with 10 mg of metolazone daily with close moni-
oring and a treatment course limited to only 3 days appears
o be safe and effective (41), resulting in a mean weight loss
f 5 kg over 5 to 6 days. When patients are on very high
D doses, halving the LD dose when a TD is added may
educe the risk of adverse effects. An aldosterone antagonist
an improve natriuresis (21) and reduce hypokalemia (25)
hen added to CDT. Additionally, chronic aldosterone
ntagonist therapy can reduce mortality in outpatients with
dvanced heart failure receiving LD monotherapy (65).
uture Studies and End Points
iven the uncertainties regarding the balance of safety
nd clinical benefit, CDT should be subjected to a prag-
atic clinical trial in fluid-overloaded inpatients with acute
ecompensated heart failure or outpatients with advanced
hronic heart failure. The strategy of adding a TD to
neffective LD therapy could be compared with placebo or
ncreasing LD doses using safety and morbidity/mortality
nd points such as days alive and free from hospitalization.
uch a trial would allow clinicians to decide if and when to
se this potentially powerful and potentially risky therapy
hat is currently recommended by major heart failure guide-
ines based on expert opinion. The National Heart, Lung,
nd Blood Institute’s Heart Failure Network could provide
he infrastructure to answer these questions, as demon-
trated by the recent DOSE trial.
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